Semaglutide shows promise in reducing alcohol cravings and consumption. Could it be a future treatment for AUD?

(HealthDay News) — Low-dose semaglutide seems to reduce craving and certain drinking outcomes in alcohol use disorder (AUD), according to a study published online Feb. 12 in JAMA Psychiatry.

Novo Nordisk is providing direct-to-patient delivery of Wegovy (semaglutide) through the NovoCare Pharmacy program.

On February 21, 2025, the US Food and Drug Administration (FDA) revised its shortage categorization of semaglutide, a glucagon-like peptide 1 ...

NovoCare Pharmacy will provide all dose strengths of Wegovy at a reduced cost of $499 per month for cash-paying patients ...

Novo Nordisk launched "My Ozempic® Era" today, a national campaign which spotlights the longstanding Ozempic® patient ...

With shortages of its blockbuster obesity now declared resolved in the USA, Denmark’s Novo Nordisk (NOV: N) is moving to make ...

As part of its ongoing efforts to ensure patients who need Wegovy, or semaglutide, injection 0.25 mg, 0.5 mg, 1 mg, 1.7 mg, and 2.4 mg can ...

The home shipments — which will be fulfilled by CenterWell Pharmacy — include Wegovy injections of 0.25 mg, 0.5 mg, 1 mg, 1.7 ...

The researchers found that low-dose semaglutide (0.25 mg/week for 4 weeks, 0.5 mg/week for 4 weeks, and 1 mg for one week) reduced the amount of alcohol consumed during a posttreatment laboratory ...

Until recently, semaglutide injection products had been ... can receive Wegovy (2.5mg, 0.5mg, 1mg, 1.7mg, and 2.4mg) at a reduced cost of $499 per month. According to the Company, the program ...